Share This Page
Drug Price Trends for STELARA
✉ Email this page to a colleague
Average Pharmacy Cost for STELARA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| STELARA 90 MG/ML SYRINGE | 57894-0061-03 | 28378.94529 | ML | 2025-05-21 |
| STELARA 90 MG/ML SYRINGE | 57894-0061-03 | 28235.89352 | ML | 2025-01-03 |
| STELARA 45 MG/0.5 ML SYRINGE | 57894-0060-03 | 28053.97911 | ML | 2025-01-03 |
| STELARA 90 MG/ML SYRINGE | 57894-0061-03 | 26968.37967 | ML | 2024-12-18 |
| STELARA 45 MG/0.5 ML SYRINGE | 57894-0060-03 | 26794.63143 | ML | 2024-12-18 |
| STELARA 90 MG/ML SYRINGE | 57894-0061-03 | 26955.68250 | ML | 2024-11-20 |
| STELARA 45 MG/0.5 ML SYRINGE | 57894-0060-03 | 26767.26308 | ML | 2024-11-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Stelara (Ustekinumab)
Introduction to Stelara
Stelara, also known as ustekinumab, is a human monoclonal antibody used as an immunosuppressant. It is produced through recombinant DNA technology and is administered via subcutaneous or intravenous routes. Stelara is primarily used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis[1].
Current Market Performance
As of 2023, the global sales of Stelara stood at USD 11,309.89 million, reflecting a historical growth rate (CAGR) of 12% from 2020 to 2023. This significant growth underscores the drug's efficacy and demand in the market for treating autoimmune diseases[1].
Market Size and Growth Projections
The global ustekinumab market was valued at USD 11.4 billion in 2023 and is projected to reach USD 18.03 billion by 2031, growing at a CAGR of 5.90% during the forecast period of 2024 to 2031. This growth is driven by increasing prevalence rates of autoimmune diseases and the expanding use of ustekinumab in various therapeutic applications[3].
Market Segmentation
The ustekinumab market is segmented based on several factors, including:
- Drug Class: Interleukin inhibitors and others.
- Demographic: Adult and pediatric.
- Application: Arthritis, colitis, lupus erythematosus, myositis multiplex with palmoplantar pustulosis, cirrhosis of the liver, sarcoidosis, diabetes, and others.
- Dosage Form: Intravenous solution and subcutaneous solution.
- End-Users: Clinics, hospitals, and others.
- Distribution Channel: Hospital pharmacy, retail pharmacy, and online pharmacy[3].
Price Negotiations and Discounts
A significant development in the pricing of Stelara is the result of the first round of Centers for Medicare & Medicaid Services (CMS) price negotiations with drugmakers. Starting January 1, 2026, the list price of Stelara for Medicare users will be reduced by nearly 66%, from $13,836 to $4,695 for a 30-day supply. This reduction is part of a broader initiative under the Inflation Reduction Act to negotiate prices for high-priced, single-source medications without generic or biosimilar competition[2][5].
Impact on Medicare and Patients
The negotiated discounts are expected to save Medicare users $1.5 billion in out-of-pocket costs and Medicare $6 billion in the first year alone. This move is seen as a significant relief for millions of seniors who rely on these drugs to treat various conditions, including heart failure, blood clots, diabetes, arthritis, and Crohn’s disease[2].
Competitive Landscape
In the Crohn's disease market, Stelara holds a significant share, with approximately $1.5 billion of the $7.4 billion in total US CD drug sales in 2022, accounting for about 20% of the market. However, the market is dynamic, with the launch of adalimumab biosimilars in 2023 and expected ustekinumab biosimilars in 2025. New treatment guidelines are also anticipated to shift first-line treatment modalities away from older anti-TNFs to newer therapies like Stelara[4].
Mechanism of Action
Stelara works by inhibiting the activity of interleukin-12 and interleukin-23, which are cytokines involved in the inflammatory process. This mechanism makes it effective in treating autoimmune diseases by reducing inflammation and modulating the immune response[1].
Future Trends and Challenges
The ustekinumab market is expected to grow due to the increasing prevalence of autoimmune diseases and the expanding therapeutic applications of the drug. However, challenges such as the introduction of biosimilars and changes in treatment guidelines could impact market dynamics. The upcoming launch of next-generation anti-IL-23 drugs may also influence Stelara's market share[3][4].
Expert Insights
"The administration’s effort to make care more affordable and improve patient access to necessary medications is commendable," stated the American College of Rheumatology, highlighting the positive impact of price negotiations on patient care[5].
Illustrative Statistics
- Global Sales: USD 11,309.89 million in 2023[1].
- CAGR: 12% from 2020 to 2023, and expected to decline thereafter[1].
- Projected Market Size: USD 18.03 billion by 2031[3].
- Discounted Price: $4,695 for a 30-day supply starting January 1, 2026, down from $13,836[2][5].
"When these lower prices go into effect, people on Medicare will save $1.5 billion in out-of-pocket costs for their prescription drugs and Medicare will save $6 billion in the first year alone," - President Biden[2].
Key Takeaways
- Market Growth: The global ustekinumab market is projected to grow at a CAGR of 5.90% from 2024 to 2031.
- Price Reductions: Stelara's list price for Medicare users will be reduced by nearly 66% starting January 1, 2026.
- Market Share: Stelara holds a significant share in the Crohn's disease market but faces competition from biosimilars and new therapies.
- Mechanism of Action: Stelara inhibits interleukin-12 and interleukin-23, reducing inflammation and modulating the immune response.
- Future Trends: The market will be influenced by increasing prevalence of autoimmune diseases, introduction of biosimilars, and changes in treatment guidelines.
FAQs
Q: What is Stelara used for? A: Stelara (ustekinumab) is used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Q: How much will the price of Stelara be reduced for Medicare users? A: The list price of Stelara for Medicare users will be reduced by nearly 66%, from $13,836 to $4,695 for a 30-day supply, starting January 1, 2026.
Q: What is the projected market size of ustekinumab by 2031? A: The global ustekinumab market is projected to reach USD 18.03 billion by 2031.
Q: What is the mechanism of action of Stelara? A: Stelara works by inhibiting the activity of interleukin-12 and interleukin-23, reducing inflammation and modulating the immune response.
Q: How will the introduction of biosimilars affect the market for Stelara? A: The introduction of biosimilars is expected to impact Stelara's market share, especially with the launch of adalimumab biosimilars in 2023 and expected ustekinumab biosimilars in 2025.
Sources Cited
- GlobalData: "The Global Drug sales of Stelara (2020 - 2026, USD Millions)"
- The Derm Digest: "List Prices of Enbrel, Stelara Slashed by Close to 70% Through Medicare Price Negotiations"
- Data Bridge Market Research: "Ustekinumab Market Size, Scope, Outlook & Growth Trends By 2031"
- Clinical Trials Arena: "Finding the Crohn's disease leader is underway with anti-interleukin-23s"
- Healio: "Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations"
More… ↓
